Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Copple

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Oncotarget|June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget|February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Archives of Toxicology|November 15, 2018
Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injuryIan M Copple, Wouter den Hollander, Giulia Callegaro, et al.
Free Radical Biology & Medicine|December 3, 2014
Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2Adedamola Olayanju, Ian M Copple, Holly K Bryan, et al.
Journal of the National Cancer Institute|December 1, 2025
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancerDylan Williams, Chandni Patel, Kate Murray, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 30, 2023
A systems approach reveals species differences in hepatic stress response capacityGiusy Russomanno, Rowena Sison-Young, Lucia A Livoti, et al.
Nature Reviews. Drug Discovery|November 22, 2019
Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive modelsRichard J Weaver, Eric A Blomme, Amy E Chadwick, et al.
Hepatology (Baltimore, Md.)|April 19, 2021
Pharmacological Activation of Nrf2 Enhances Functional Liver RegenerationBenjamin K Y Chan, Mohamed Elmasry, Shiva S Forootan, et al.
Journal of Hepatology|February 8, 2022
Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicityAhmed Ghallab, Reham Hassan, Ute Hofmann, et al.
Nature Reviews. Drug Discovery|October 28, 2025
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safetyChristopher E Goldring, Giusy Russomanno, Carmen Pin, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Oncotarget|June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget|February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Archives of Toxicology|November 15, 2018
Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injuryIan M Copple, Wouter den Hollander, Giulia Callegaro, et al.
Free Radical Biology & Medicine|December 3, 2014
Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2Adedamola Olayanju, Ian M Copple, Holly K Bryan, et al.
Journal of the National Cancer Institute|December 1, 2025
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancerDylan Williams, Chandni Patel, Kate Murray, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 30, 2023
A systems approach reveals species differences in hepatic stress response capacityGiusy Russomanno, Rowena Sison-Young, Lucia A Livoti, et al.
Nature Reviews. Drug Discovery|November 22, 2019
Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive modelsRichard J Weaver, Eric A Blomme, Amy E Chadwick, et al.
Hepatology (Baltimore, Md.)|April 19, 2021
Pharmacological Activation of Nrf2 Enhances Functional Liver RegenerationBenjamin K Y Chan, Mohamed Elmasry, Shiva S Forootan, et al.
Journal of Hepatology|February 8, 2022
Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicityAhmed Ghallab, Reham Hassan, Ute Hofmann, et al.
Nature Reviews. Drug Discovery|October 28, 2025
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safetyChristopher E Goldring, Giusy Russomanno, Carmen Pin, et al.
Pageof 5